Denali Therapeutics Inc.
Denali Therapeutics discovers and develops medicines for people living with serious diseases, including neurodegenerative diseases and lysosomal storage disorders. Its proprietary TransportVehicle technology is designed to deliver large-molecule biotherapeutics, including enzymes, oligonucleotides and antibodies, across the blood-brain barrier and to other tissues. The company’s platforms include Enzyme TransportVehicle, Oligonucleotide TransportVehicle and Antibody TransportVehicle. Its programs include tividenofusp alfa for Hunter syndrome, DNL126 for Sanfilippo syndrome type A, and candidates for Alzheimer’s disease, Parkinson’s disease, FTD-GRN and Pompe disease. Denali makes money through potential product sales and partnerships. It plans to commercialize its product candidates, if approved, in key markets, while also leveraging partners or distributors. Active collaborations include development and commercialization arrangements with Takeda and Biogen. Denali also operates a clinical biomanufacturing facility in Salt Lake City, Utah. It is headquartered in South San Francisco, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $DNLI in the last 30 days.
See all $DNLI insider activity →Morgan Stanley kept its Overweight rating on Denali Therapeutics and increased its price target to $42 from $40, suggesting a 115.9% upside from the Nov 3 close of $19.45, according to the firm.
Wedbush kept Denali Therapeutics at Outperform, raising its price target to $24 from $23, a 4.3% increase. This implies 23.4% upside from the Nov 3 close of $19.45.
BTIG reaffirms its Buy rating and $39 price target for Denali Therapeutics, implying a 100.5% upside from its Nov 3 close of $19.45.
Over the past 7 days, AlphAI's AI scored 10 news stories mentioning DNLI (Denali Therapeutics Inc.). Coverage has skewed bullish: 8 bullish, 2 neutral, and 0 bearish.
Recent DNLI coverage spans financial news, earnings and mergers & acquisitions.
Morgan Stanley kept its Overweight rating on Denali Therapeutics and increased its price target to $42 from $40, suggesting a 115.9% upside from the Nov 3 close of $19.45, according to the firm.
Wedbush kept Denali Therapeutics at Outperform, raising its price target to $24 from $23, a 4.3% increase. This implies 23.4% upside from the Nov 3 close of $19.45.
BTIG reaffirms its Buy rating and $39 price target for Denali Therapeutics, implying a 100.5% upside from its Nov 3 close of $19.45.
Earnings beat expectations with solid cash and one-time voucher proceeds.
Guidance lift signals stronger commercial traction for AVLAYAH and pipeline momentum.
AlphAI scores every news story that mentions DNLI with an AI model for sentiment and relevance, and aggregates insider trades from Denali Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Morgan Stanley kept its Overweight rating on Denali Therapeutics and increased its price target to $42 from $40, suggesting a 115.9% upside from the Nov 3 close of $19.45, according to the firm.
1 min readWedbush kept Denali Therapeutics at Outperform, raising its price target to $24 from $23, a 4.3% increase. This implies 23.4% upside from the Nov 3 close of $19.45.
1 min readBTIG reaffirms its Buy rating and $39 price target for Denali Therapeutics, implying a 100.5% upside from its Nov 3 close of $19.45.
1 min readDenali Therapeutics reported Q3 revenue growth due to expanded coverage and patient transitions. AVLAYAH's J-code became effective, simplifying billing. Revenue is expected to rise steadily. Sanfilippo syndrome type A trial data to be presented in 2027. Alzheimer's programs in clinical trials. Q3 net income was $70.1M, with $1.01B in cash. Company aims to build two commercial brands and advance multiple programs by 2028.
3 min readDenali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights • AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter • Continued growth expectations drive Q4 2026 net produ
2 min readDenali Therapeutics (DNLI) announced its drug AVLAYAH (tividenofusp alfa-eknm) won the 2026 Prix Galien USA Best Biotechnology Product. AVLAYAH, FDA-approved in March 2026, treats Hunter syndrome by crossing the blood-brain barrier. The company's stock is trading at $18.86, down 2.35%.
2 min readDenali Therapeutics' AVLAYAH, the first FDA-approved treatment for Hunter syndrome in nearly 20 years, won the 2026 Prix Galien USA 'Best Biotechnology Product' award. The drug uses Denali's TransportVehicle technology to cross the blood-brain barrier, offering potential for treating other neurodegenerative diseases. AVLAYAH received FDA accelerated approval in March 2026 for pediatric patients with Hunter syndrome, with continued approval contingent on confirmatory study results.
5 min readDenali Therapeutics (DNLI) reported Q2 2026 net product revenue of $3.6 million from the first full quarter of AVLAYAH in the US. It guided Q3 revenue to $10 million to $12 million and said pro forma cash and securities were $1.1 billion after a $195 million priority review voucher sale. R&D was $97.0 million; net loss was $127.6 million.
6 min readDenali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue • Advanced TransportVehicle™ portfolio with two Alzheimer’s
6 min readDenali Therapeutics Inc. (DNLI) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. dnli-20260727 0001714899 FALSE 0001714899 2026-07-27 2026-07-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
2 min read
